Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Carfilzomib API

Product
  • Therapeutic Category Oncology

  • CAS Number

    868540-17-4

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF, China DMF, EU, Japan DMF, Korea DMF

Mechanism of Action

Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth.

Indication

KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Carfilzomib
Select Regulatory Requirements
Select Purpose

Related APIs

Capivasertib

Oncology

arrow

Abiraterone Acetate

Oncology

arrow

Azacitidine

Oncology

arrow

Bendamustine Hydrochloride

Oncology

arrow

Bortezomib

Oncology

arrow

Cabazitaxel

Oncology

arrow

Cabozantinib S-Malate

Oncology

arrow

Capecitabine

Oncology

arrow

Carfilzomib

Oncology

arrow

Decitabine

Oncology

arrow

Deucravacitinib

Oncology

arrow

Eribulin Mesylate

Oncology

arrow

Cabozantinib Hydrochloride

Oncology

arrow

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.
Carfilzomib  API Manufacturer and Supplier | CAS 868540-17-4  - Dr. Reddy's